日本血凝病毒包膜包裹的微小RNA-34a-5p通过抑制生存素强烈诱导恶性脑膜瘤细胞凋亡。
Hemagglutinating virus of Japan envelope encapsulating microRNA-34a-5p robustly induces apoptosis of malignant meningioma cells by suppressing survivin.
作者信息
Ishikawa Takaaki, Matsuda Masahide, Kaneda Yasufumi, Ishikawa Eiichi
机构信息
Graduate School of Comprehensive Human Sciences, Doctoral Program in Medical Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Department of Neurosurgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
出版信息
J Neurooncol. 2025 Jul 21. doi: 10.1007/s11060-025-05172-0.
PURPOSE
Malignant meningiomas are characterized by high recurrence rates and limited therapeutic options beyond surgery and radiation. This study aimed to develop a novel nucleic acid-based therapeutic approach for malignant meningiomas and to evaluate its efficacy both in vitro and in vivo.
METHODS
IOMM-Lee and HKBMM cell lines were used as models of malignant meningioma. Inhibitory effects of hemagglutinating virus of Japan envelope (HVJ-E) and microRNA-34a-5p (miR-34a-5p) were assessed using cell viability assays, apoptosis assays, RT-qPCR, and western blotting. Finally, the tumor suppressive effect of HVJ-E encapsulating miR-34a-5p was evaluated using a subcutaneous xenograft model in nude mice.
RESULT
HVJ-E significantly reduced viability of malignant meningioma cells. Furthermore, HVJ-E encapsulating miR-34a-5p demonstrated enhanced anti-tumor activity by inducing apoptosis through downregulation of survivin expression. This tumor-suppressive effect was also confirmed in a subcutaneous mouse model.
CONCLUSION
Our findings indicate that HVJ-E encapsulating miR-34a-5p effectively inhibits the growth of malignant meningioma cells both in vitro and in vivo. This novel combination therapy holds promise as a potential treatment strategy for malignant meningiomas.
目的
恶性脑膜瘤的特点是复发率高,且除手术和放疗外治疗选择有限。本研究旨在开发一种针对恶性脑膜瘤的新型核酸治疗方法,并在体外和体内评估其疗效。
方法
使用IOMM-Lee和HKBMM细胞系作为恶性脑膜瘤模型。通过细胞活力测定、凋亡测定、RT-qPCR和蛋白质印迹法评估日本血凝病毒包膜(HVJ-E)和微小RNA-34a-5p(miR-34a-5p)的抑制作用。最后,使用裸鼠皮下异种移植模型评估封装miR-34a-5p的HVJ-E的肿瘤抑制作用。
结果
HVJ-E显著降低恶性脑膜瘤细胞的活力。此外,封装miR-34a-5p的HVJ-E通过下调生存素表达诱导凋亡,表现出增强的抗肿瘤活性。这种肿瘤抑制作用在皮下小鼠模型中也得到了证实。
结论
我们的研究结果表明,封装miR-34a-5p的HVJ-E在体外和体内均能有效抑制恶性脑膜瘤细胞的生长。这种新型联合疗法有望成为恶性脑膜瘤的潜在治疗策略。